Table 1. Patient characteristics at the initiation of NVP plus TDF plus FTC (or 3TC) as a switch strategy (n = 341).
| Age (yrs, mean [SD]) | 42.2 (8.7) |
| Gender (male, %) | 246 (72) |
| Risk category for HIV acquisition (n, %) | |
| MSM | 125 (37.3) |
| Intravenous Drug Users | 92 (27.5) |
| Heterosexual | 92 (27.5) |
| Other | 32 (9.4) |
| Hepatitis B or C Co-infection (n, %) | |
| Hep C | 98 (29.8) |
| Hep B | 25 (7.7) |
| Pregnancy | 7 (7.4) |
| Nadir CD4 cell count (cells, mean [SD]) | 239 (148) |
| Baseline CD4 cell count (cells, median [IQR]) | 492 (331,7) |
| Time of HIV-1 infection (months, mean [SD]) | 128 (69) |
| Time with undetectable viral load at regimen initiation | 48 (33) |
| (months, mean [SD]) | |
| Prior Antiretroviral exposure (n of drugs, median [IQR]) | 6 (4,8) |
| Number of prior NRTI | 4 (2,5) |
| Number of prior NNRTI | 1 (1,1) |
| Number of prior PI | 1 (1,2) |
| Prior NRTI mono or dual therapy (n, %) | 146 (43) |
| Both NRTI mono and dual NRTI prior therapy | 60 (18) |
| Prior virologic failures documented (n, %) | 79 (24) |
| Prior NNRTI documented treatment interruption (n, %) | 99 (29.2) |
| NNRTI interruption only once | 1 (23) |
| More than 1 NNRTI interruption | 44 (13) |
| Drug previously interrupted: | |
| Nevirapine | 60 (18) |
| Efavirenz | 18 (5) |
| Viral load at baseline < 50 copies/mL (n, %) * | 264 (78.3) |
| Lamivudine present in the last regimen | 193 (57) |
| Emtricitabine present in the last regimen | 66 (19) |
| Tenofovir present in the last regimen | 126 (37) |
| Nevirapine present in the last regimen | 173 (51) |
| Drug substituted by NVP | |
| Efavirenz | 56 (33) |
| Protease inhibitor (indinavir, nelfinavir, saquinavir) | 40 (24) |
| Boosted protease inhibitor (lopinavir, atazanavir, darunavir) | 60 (36) |
| Other (raltegravir, etravirine) | 12 (7) |
| Received 3TC + NVP + TDF | 159 (47) |
| Received FTC + NVP + TDF | 182 (53) |
Data are median (IQR) or n (%).
* Some individuals in the early calendar years had an undetectable viral load at baseline, but with tests using at that moment a threshold of 80 or 200 copies/mL.
MSM: Men having sex with men; NRTI: Nucleos(t)ide reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor.